Cambient Family Office LLC Purchases New Position in Stryker Corporation $SYK

Cambient Family Office LLC purchased a new stake in Stryker Corporation (NYSE:SYK) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 14,584 shares of the medical technology company’s stock, valued at approximately $5,139,000.

Several other hedge funds have also bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Stryker during the 4th quarter worth approximately $1,822,272,000. Wellington Management Group LLP lifted its stake in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Corient Private Wealth LLC lifted its stake in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the period. Alliancebernstein L.P. boosted its holdings in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Finally, Strive Asset Management LLC acquired a new stake in Stryker during the third quarter valued at $227,389,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $308.62 on Friday. The stock has a market capitalization of $118.31 billion, a P/E ratio of 35.72, a P/E/G ratio of 1.93 and a beta of 0.78. The company’s fifty day moving average price is $314.43 and its 200 day moving average price is $341.94. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SYK. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Evercore set a $355.00 target price on shares of Stryker in a research note on Friday, May 1st. Wells Fargo & Company dropped their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. William Blair restated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Finally, BTIG Research reduced their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.